

Coverage & Billing Information for the 2023 Quarterly Code Update

BACKGROUND

Iowa Medicaid has reviewed the **Q4 2023** Billing Code Update to determine coverage and billing guidelines. The Iowa Medicaid coverage and billing information provided in this bulletin is effective **October 1, 2023**. This bulletin serves as a notice of the following information:

Table 1

- New Current Procedural Terminology (CPT[®]) and Healthcare Common Procedure Coding System (HCPCS) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **October 1, 2023**.

Table 2

- New Current Dental Terminology (CDT[®]) codes included in the Q1 2023 code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 3

- International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Coverage and billing for these codes applies to dates of service on or after **October 1, 2023**.

Table 4

- International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) codes. Coverage and billing for these codes applies to dates of service on or after **October 1, 2023**.

Table 5

- Modifiers included in the code update. Coverage and billing information for these codes applies to dates of service on or after **N/A**.

Table 6

- CPT[®], CDT[®], & HCPCS codes that would be considered Outpatient Hospital on or after **October 1, 2023**.

Table 7

- CPT[®], CDT[®], & HCPCS codes that require Pre-Pay or Post-Pay claim review for Fee For Service (FFS) (traditional Medicaid) effective **October 1, 2023**.

Table 8

- Non-Covered Codes - CPT[®], CDT[®], HCPCS, ICD-10-CM & ICD-10-PCS codes that have been thoroughly reviewed and Iowa Medicaid has decided not to cover effective **October 1, 2023**.

Table 9

- Deleted Codes - CPT[®], CDT[®], HCPCS, ICD-10-CM & ICD-10-PCS codes that have been discontinued effective **September 30, 2023**.

The standard global billing procedures and edits apply to the new codes unless special billing guidance is otherwise noted. Reimbursement, prior authorization (PA), and billing information apply to services delivered under the fee-for-service (FFS) delivery system. Questions about FFS PA should be directed to Iowa Medicaid Provider Services at 1-800-338-7909 or via email at imeproviderservices@dhs.state.ia.us.

Managed Care Organization (MCOs) establish and publish reimbursement, PA, and billing information within the managed care delivery system. Questions about managed care PA should be directed to the MCP with which the member is enrolled.

Amerigroup Iowa, Inc.:

- Provider Services: 1-800-454-3730
- Provider email: iowamedicaid@amerigroup.com
- Website: <https://providers.amerigroup.com/ia>

Iowa Total Care:

- Provider Services: 1-833-404-1061
- Provider email: Providers may send email using their account on the ITC website.
- Website: <https://www.iowatotalcare.com>

The **Q4 2023** code update may include modifications to descriptions for some existing HCPCS/CPT codes. These modifications are available for reference or download from the CMS website at www.cms.gov.

The **Q4** code update also includes a list of deleted codes. These codes are available for reference or download from the CMS website at cms.gov. If there is a replacement code, Iowa Medicaid has added the replacement code for which there were deleted codes effective as of **September 30, 2023**.

Medically Unlikely Edits are the maximum units of service that a provider would report under most circumstances for a single beneficiary on a single date of service. The **max units** listed in the tables below are derived from the quarterly [Medicaid NCCI Edits](#) released by CMS.

Iowa Medicaid will update the fee schedule as rates become available.

Table 1 – CPT® & HCPCS Codes

[Back to top](#)

Code	Description	Effective Date	Special Billing Information
0408U	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])	10/1/2023	Max Units: 1
A9573	Injection, gadopichlenol, 1 ml	10/1/2023	Min Age: 2 Max Units: 1
A9603	Injection, pafolacianine, 0.1 mg	10/1/2023	Min Age: 2 Max Units: 1
A9697	Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose	10/1/2023	Min Age: 2 Max Units: 1
B4148	Enteral feeding supply kit; elastomeric control fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	10/1/2023	Max Units: 1
C9152	Injection, aripiprazole, (abilify asimtufii), 1 mg	10/1/2023	Min Age: 18 Max Units: 960
C9153	Injection, amisulpride, 1 mg	10/1/2023	Min Age: 18 Max Units: 10
C9154	Injection, buprenorphine extended-release (brixadi), 1 mg	10/1/2023	Min Age: 18 Max Units: 128
C9156	Flotufolastat f 18, diagnostic, 1 millicurie	10/1/2023	Min Age: 18 Max Units: 8 Male Only
C9158	Injection, risperidone, (uzedy), 1 mg	10/1/2023	Min Age: 18 Max Units: 250
J0801	Injection, corticotropin (acthar gel), up to 40 units	10/1/2023	Max Units: 3
J0802	Injection, corticotropin (ani), up to 40 units	10/1/2023	Max Units: 3
J0874	Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg	10/1/2023	Min Age: 1 Max Units: 1500
J0889	Daprodustat, oral, 1 mg, (for esrd on dialysis)	10/1/2023	Min Age: 18 Max Units: 24
J2359	Injection, olanzapine, 0.5 mg	10/1/2023	Min Age: 13 Max Units: 1
J7214	Injection, factor viii/von willebrand factor complex, recombinant (altuviio), per factor viii i.u.	10/1/2023	Max Units: 1
J7519	Injection, mycophenolate mofetil, 10 mg	10/1/2023	Max Units: 1

J9064	Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg	10/1/2023	Min Age: 18 Max Units: 60
L1681	Hip orthosis, bil hip joints and thigh cuffs, adjustable flexion, extension, abduction control of hip joint, postop hip abd type, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized	10/1/2023	Max Units: 1

*Covid Related Code

[Back to top](#)

Table 2 – CDT©

[Back to top](#)

Code	Description	Effective Date
N/A	N/A	N/A

[Back to top](#)

Table 3 – ICD-10-CM Codes

[Back to top](#)

Code	Description	Effective Date
A41.54	Sepsis due to Acinetobacter baumannii	10/1/2023
B96.83	Acinetobacter baumannii as the cause of diseases classified elsewhere	10/1/2023
D13.91	Familial adenomatous polyposis	10/1/2023
D13.99	Benign neoplasm of ill-defined sites within the digestive system	10/1/2023
D48.110	Desmoid tumor of head and neck	10/1/2023
D48.111	Desmoid tumor of chest wall	10/1/2023
D48.112	Desmoid tumor, intrathoracic	10/1/2023
D48.113	Desmoid tumor of abdominal wall	10/1/2023
D48.114	Desmoid tumor, intraabdominal	10/1/2023
D48.115	Desmoid tumor of upper extremity and shoulder girdle	10/1/2023
D48.116	Desmoid tumor of lower extremity and pelvic girdle	10/1/2023
D48.117	Desmoid tumor of back	10/1/2023
D48.118	Desmoid tumor of other site	10/1/2023
D48.119	Desmoid tumor of unspecified site	10/1/2023
D48.19	Other specified neoplasm of uncertain behavior of connective and other soft tissue	10/1/2023
D57.04	Hb-SS disease with dactylitis	10/1/2023
D57.214	Sickle-cell/Hb-C disease with dactylitis	10/1/2023
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	10/1/2023
D57.434	Sickle-cell thalassemia beta zero with dactylitis	10/1/2023
D57.454	Sickle-cell thalassemia beta plus with dactylitis	10/1/2023
D57.814	Other sickle-cell disorders with dactylitis	10/1/2023
D61.02	Shwachman-Diamond syndrome	10/1/2023

D89.84	IgG4-related disease	10/1/2023
E20.810	Autosomal dominant hypocalcemia	10/1/2023
E20.811	Secondary hypoparathyroidism in diseases classified elsewhere	10/1/2023
E20.812	Autoimmune hypoparathyroidism	10/1/2023
E20.818	Other specified hypoparathyroidism due to impaired parathyroid hormone secretion	10/1/2023
E20.819	Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified	10/1/2023
E20.89	Other specified hypoparathyroidism	10/1/2023
E74.05	Lysosome-associated membrane protein 2 [LAMP2] deficiency	10/1/2023
E75.27	Pelizaeus-Merzbacher disease	10/1/2023
E75.28	Canavan disease	10/1/2023
E79.81	Aicardi-Goutières syndrome	10/1/2023
E79.82	Hereditary xanthinuria	10/1/2023
E79.89	Other specified disorders of purine and pyrimidine metabolism	10/1/2023
E88.43	Disorders of mitochondrial tRNA synthetases	10/1/2023
E88.810	Metabolic syndrome	10/1/2023
E88.811	Insulin resistance syndrome, Type A	10/1/2023
E88.818	Other insulin resistance	10/1/2023
E88.819	Insulin resistance, unspecified	10/1/2023
E88.A	Wasting disease (syndrome) due to underlying condition	10/1/2023
G11.5	Hypomyelination - hypogonadotropic hypogonadism - hypodontia	10/1/2023
G11.6	Leukodystrophy with vanishing white matter disease	10/1/2023
G20.A1	Parkinson's disease without dyskinesia, without mention of fluctuations	10/1/2023
G20.A2	Parkinson's disease without dyskinesia, with fluctuations	10/1/2023
G20.B1	Parkinson's disease with dyskinesia, without mention of fluctuations	10/1/2023
G20.B2	Parkinson's disease with dyskinesia, with fluctuations	10/1/2023
G20.C	Parkinsonism, unspecified	10/1/2023
G23.3	Hypomyelination with atrophy of the basal ganglia and cerebellum	10/1/2023
G31.80	Leukodystrophy, unspecified	10/1/2023
G31.86	Alexander disease	10/1/2023
G37.81	Myelin oligodendrocyte glycoprotein antibody disease	10/1/2023
G37.89	Other specified demyelinating diseases of central nervous system	10/1/2023
G40.C01	Lafora progressive myoclonus epilepsy, not intractable, with status epilepticus	10/1/2023
G40.C09	Lafora progressive myoclonus epilepsy, not intractable, without status epilepticus	10/1/2023
G40.C11	Lafora progressive myoclonus epilepsy, intractable, with status epilepticus	10/1/2023
G40.C19	Lafora progressive myoclonus epilepsy, intractable, without status epilepticus	10/1/2023

G43.E01	Chronic migraine with aura, not intractable, with status migrainosus	10/1/2023
G43.E09	Chronic migraine with aura, not intractable, without status migrainosus	10/1/2023
G43.E11	Chronic migraine with aura, intractable, with status migrainosus	10/1/2023
G43.E19	Chronic migraine with aura, intractable, without status migrainosus	10/1/2023
G90.B	LMNBI-related autosomal dominant leukodystrophy	10/1/2023
G93.42	Megaloencephalic leukoencephalopathy with subcortical cysts	10/1/2023
G93.43	Leukoencephalopathy with calcifications and cysts	10/1/2023
G93.44	Adult-onset leukodystrophy with axonal spheroids	10/1/2023
H36.811	Nonproliferative sickle-cell retinopathy, right eye	10/1/2023
H36.812	Nonproliferative sickle-cell retinopathy, left eye	10/1/2023
H36.813	Nonproliferative sickle-cell retinopathy, bilateral	10/1/2023
H36.819	Nonproliferative sickle-cell retinopathy, unspecified eye	10/1/2023
H36.821	Proliferative sickle-cell retinopathy, right eye	10/1/2023
H36.822	Proliferative sickle-cell retinopathy, left eye	10/1/2023
H36.823	Proliferative sickle-cell retinopathy, bilateral	10/1/2023
H36.829	Proliferative sickle-cell retinopathy, unspecified eye	10/1/2023
H36.89	Other retinal disorders in diseases classified elsewhere	10/1/2023
H50.621	Inferior oblique muscle entrapment, right eye	10/1/2023
H50.622	Inferior oblique muscle entrapment, left eye	10/1/2023
H50.629	Inferior oblique muscle entrapment, unspecified eye	10/1/2023
H50.631	Inferior rectus muscle entrapment, right eye	10/1/2023
H50.632	Inferior rectus muscle entrapment, left eye	10/1/2023
H50.639	Inferior rectus muscle entrapment, unspecified eye	10/1/2023
H50.641	Lateral rectus muscle entrapment, right eye	10/1/2023
H50.642	Lateral rectus muscle entrapment, left eye	10/1/2023
H50.649	Lateral rectus muscle entrapment, unspecified eye	10/1/2023
H50.651	Medial rectus muscle entrapment, right eye	10/1/2023
H50.652	Medial rectus muscle entrapment, left eye	10/1/2023
H50.659	Medial rectus muscle entrapment, unspecified eye	10/1/2023
H50.661	Superior oblique muscle entrapment, right eye	10/1/2023
H50.662	Superior oblique muscle entrapment, left eye	10/1/2023
H50.669	Superior oblique muscle entrapment, unspecified eye	10/1/2023
H50.671	Superior rectus muscle entrapment, right eye	10/1/2023
H50.672	Superior rectus muscle entrapment, left eye	10/1/2023
H50.679	Superior rectus muscle entrapment, unspecified eye	10/1/2023

H50.681	Extraocular muscle entrapment, unspecified, right eye	10/1/2023
H50.682	Extraocular muscle entrapment, unspecified, left eye	10/1/2023
H50.689	Extraocular muscle entrapment, unspecified, unspecified eye	10/1/2023
H57.8A1	Foreign body sensation, right eye	10/1/2023
H57.8A2	Foreign body sensation, left eye	10/1/2023
H57.8A3	Foreign body sensation, bilateral eyes	10/1/2023
H57.8A9	Foreign body sensation, unspecified eye	10/1/2023
I1A.0	Resistant hypertension	10/1/2023
I20.81	Angina pectoris with coronary microvascular dysfunction	10/1/2023
I20.89	Other forms of angina pectoris	10/1/2023
I21.B	Myocardial infarction with coronary microvascular dysfunction	10/1/2023
I24.81	Acute coronary microvascular dysfunction	10/1/2023
I24.89	Other forms of acute ischemic heart disease	10/1/2023
I25.85	Chronic coronary microvascular dysfunction	10/1/2023
I47.10	Supraventricular tachycardia, unspecified	10/1/2023
I47.11	Inappropriate sinus tachycardia, so stated	10/1/2023
I47.19	Other supraventricular tachycardia	10/1/2023
J15.61	Pneumonia due to <i>Acinetobacter baumannii</i>	10/1/2023
J15.69	Pneumonia due to other Gram-negative bacteria	10/1/2023
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	10/1/2023
J44.89	Other specified chronic obstructive pulmonary disease	10/1/2023
J4A.0	Restrictive allograft syndrome	10/1/2023
J4A.8	Other chronic lung allograft dysfunction	10/1/2023
J4A.9	Chronic lung allograft dysfunction, unspecified	10/1/2023
K35.200	Acute appendicitis with generalized peritonitis, without perforation or abscess	10/1/2023
K35.201	Acute appendicitis with generalized peritonitis, with perforation, without abscess	10/1/2023
K35.209	Acute appendicitis with generalized peritonitis, without abscess, unspecified as to perforation	10/1/2023
K35.210	Acute appendicitis with generalized peritonitis, without perforation, with abscess	10/1/2023
K35.211	Acute appendicitis with generalized peritonitis, with perforation and abscess	10/1/2023
K35.219	Acute appendicitis with generalized peritonitis, with abscess, unspecified as to perforation	10/1/2023
K63.8211	Small intestinal bacterial overgrowth, hydrogen-subtype	10/1/2023
K63.8212	Small intestinal bacterial overgrowth, hydrogen sulfide-subtype	10/1/2023
K63.8219	Small intestinal bacterial overgrowth, unspecified	10/1/2023
K63.822	Small intestinal fungal overgrowth	10/1/2023
K63.829	Intestinal methanogen overgrowth, unspecified	10/1/2023

K68.2	Retroperitoneal fibrosis	10/1/2023
K68.3	Retroperitoneal hematoma	10/1/2023
K90.821	Short bowel syndrome with colon in continuity	10/1/2023
K90.822	Short bowel syndrome without colon in continuity	10/1/2023
K90.829	Short bowel syndrome, unspecified	10/1/2023
K90.83	Intestinal failure	10/1/2023
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	10/1/2023
M80.0B1D	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing	10/1/2023
M80.0B1G	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
M80.0B1K	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion	10/1/2023
M80.0B1P	Age-related osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion	10/1/2023
M80.0B1S	Age-related osteoporosis with current pathological fracture, right pelvis, sequela	10/1/2023
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	10/1/2023
M80.0B2D	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing	10/1/2023
M80.0B2G	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
M80.0B2K	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion	10/1/2023
M80.0B2P	Age-related osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion	10/1/2023
M80.0B2S	Age-related osteoporosis with current pathological fracture, left pelvis, sequela	10/1/2023
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	10/1/2023
M80.0B9D	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing	10/1/2023
M80.0B9G	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
M80.0B9K	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion	10/1/2023
M80.0B9P	Age-related osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion	10/1/2023

M80.0B9S	Age-related osteoporosis with current pathological fracture, unspecified pelvis, sequela	10/1/2023
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	10/1/2023
M80.8B1D	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with routine healing	10/1/2023
M80.8B1G	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
M80.8B1K	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with nonunion	10/1/2023
M80.8B1P	Other osteoporosis with current pathological fracture, right pelvis, subsequent encounter for fracture with malunion	10/1/2023
M80.8B1S	Other osteoporosis with current pathological fracture, right pelvis, sequela	10/1/2023
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	10/1/2023
M80.8B2D	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with routine healing	10/1/2023
M80.8B2G	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
M80.8B2K	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with nonunion	10/1/2023
M80.8B2P	Other osteoporosis with current pathological fracture, left pelvis, subsequent encounter for fracture with malunion	10/1/2023
M80.8B2S	Other osteoporosis with current pathological fracture, left pelvis, sequela	10/1/2023
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	10/1/2023
M80.8B9D	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with routine healing	10/1/2023
M80.8B9G	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with delayed healing	10/1/2023
M80.8B9K	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with nonunion	10/1/2023
M80.8B9P	Other osteoporosis with current pathological fracture, unspecified pelvis, subsequent encounter for fracture with malunion	10/1/2023
M80.8B9S	Other osteoporosis with current pathological fracture, unspecified pelvis, sequela	10/1/2023
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	10/1/2023
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	10/1/2023
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	10/1/2023
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	10/1/2023
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	10/1/2023
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	10/1/2023

N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	10/1/2023
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	10/1/2023
N04.21	Primary membranous nephropathy with nephrotic syndrome	10/1/2023
N04.22	Secondary membranous nephropathy with nephrotic syndrome	10/1/2023
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	10/1/2023
N06.20	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	10/1/2023
N06.21	Primary membranous nephropathy with isolated proteinuria	10/1/2023
N06.22	Secondary membranous nephropathy with isolated proteinuria	10/1/2023
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	10/1/2023
O26.641	Intrahepatic cholestasis of pregnancy, first trimester	10/1/2023
O26.642	Intrahepatic cholestasis of pregnancy, second trimester	10/1/2023
O26.643	Intrahepatic cholestasis of pregnancy, third trimester	10/1/2023
O26.649	Intrahepatic cholestasis of pregnancy, unspecified trimester	10/1/2023
O90.41	Hepatorenal syndrome following labor and delivery	10/1/2023
O90.49	Other postpartum acute kidney failure	10/1/2023
Q44.70	Other congenital malformation of liver, unspecified	10/1/2023
Q44.71	Alagille syndrome	10/1/2023
Q44.79	Other congenital malformations of liver	10/1/2023
Q75.001	Craniosynostosis unspecified, unilateral	10/1/2023
Q75.002	Craniosynostosis unspecified, bilateral	10/1/2023
Q75.009	Craniosynostosis unspecified	10/1/2023
Q75.01	Sagittal craniosynostosis	10/1/2023
Q75.021	Coronal craniosynostosis unilateral	10/1/2023
Q75.022	Coronal craniosynostosis bilateral	10/1/2023
Q75.029	Coronal craniosynostosis unspecified	10/1/2023
Q75.03	Metopic craniosynostosis	10/1/2023
Q75.041	Lambdoid craniosynostosis, unilateral	10/1/2023
Q75.042	Lambdoid craniosynostosis, bilateral	10/1/2023
Q75.049	Lambdoid craniosynostosis, unspecified	10/1/2023
Q75.051	Cloverleaf skull	10/1/2023
Q75.052	Pansynostosis	10/1/2023
Q75.058	Other multi-suture craniosynostosis	10/1/2023
Q75.08	Other single-suture craniosynostosis	10/1/2023
Q87.83	Bardet-Biedl syndrome	10/1/2023
Q87.84	Laurence-Moon syndrome	10/1/2023

Q87.85	MED13L syndrome	10/1/2023
Q93.52	Phelan-McDermid syndrome	10/1/2023
R09.A0	Foreign body sensation, unspecified	10/1/2023
R09.A1	Foreign body sensation, nose	10/1/2023
R09.A2	Foreign body sensation, throat	10/1/2023
R09.A9	Foreign body sensation, other site	10/1/2023
R40.2A	Nontraumatic coma due to underlying condition	10/1/2023
R92.30	Dense breasts, unspecified	10/1/2023
R92.311	Mammographic fatty tissue density, right breast	10/1/2023
R92.312	Mammographic fatty tissue density, left breast	10/1/2023
R92.313	Mammographic fatty tissue density, bilateral breasts	10/1/2023
R92.321	Mammographic fibroglandular density, right breast	10/1/2023
R92.322	Mammographic fibroglandular density, left breast	10/1/2023
R92.323	Mammographic fibroglandular density, bilateral breasts	10/1/2023
R92.331	Mammographic heterogeneous density, right breast	10/1/2023
R92.332	Mammographic heterogeneous density, left breast	10/1/2023
R92.333	Mammographic heterogeneous density, bilateral breasts	10/1/2023
R92.341	Mammographic extreme density, right breast	10/1/2023
R92.342	Mammographic extreme density, left breast	10/1/2023
R92.343	Mammographic extreme density, bilateral breasts	10/1/2023
T56.821A	Toxic effect of gadolinium, accidental (unintentional), initial encounter	10/1/2023
T56.821D	Toxic effect of gadolinium, accidental (unintentional), subsequent encounter	10/1/2023
T56.821S	Toxic effect of gadolinium, accidental (unintentional), sequela	10/1/2023
T56.822A	Toxic effect of gadolinium, intentional self-harm, initial encounter	10/1/2023
T56.822D	Toxic effect of gadolinium, intentional self-harm, subsequent encounter	10/1/2023
T56.822S	Toxic effect of gadolinium, intentional self-harm, sequela	10/1/2023
T56.823A	Toxic effect of gadolinium, assault, initial encounter	10/1/2023
T56.823D	Toxic effect of gadolinium, assault, subsequent encounter	10/1/2023
T56.823S	Toxic effect of gadolinium, assault, sequela	10/1/2023
T56.824A	Toxic effect of gadolinium, undetermined, initial encounter	10/1/2023
T56.824D	Toxic effect of gadolinium, undetermined, subsequent encounter	10/1/2023
T56.824S	Toxic effect of gadolinium, undetermined, sequela	10/1/2023
W44.8XXA	Other foreign body entering into or through a natural orifice, initial encounter	10/1/2023
W44.8XXD	Other foreign body entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.8XXS	Other foreign body entering into or through a natural orifice, sequela	10/1/2023

W44.9XXA	Unspecified foreign body entering into or through a natural orifice, initial encounter	10/1/2023
W44.9XXD	Unspecified foreign body entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.9XXS	Unspecified foreign body entering into or through a natural orifice, sequela	10/1/2023
W44.A0XA	Battery unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.A0XD	Battery unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.A0XS	Battery unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.A1XA	Button battery entering into or through a natural orifice, initial encounter	10/1/2023
W44.A1XD	Button battery entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.A1XS	Button battery entering into or through a natural orifice, sequela	10/1/2023
W44.A9XA	Other batteries entering into or through a natural orifice, initial encounter	10/1/2023
W44.A9XD	Other batteries entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.A9XS	Other batteries entering into or through a natural orifice, sequela	10/1/2023
W44.B0XA	Plastic object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.B0XD	Plastic object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B0XS	Plastic object unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.B1XA	Plastic bead entering into or through a natural orifice, initial encounter	10/1/2023
W44.B1XD	Plastic bead entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B1XS	Plastic bead entering into or through a natural orifice, sequela	10/1/2023
W44.B2XA	Plastic coin entering into or through a natural orifice, initial encounter	10/1/2023
W44.B2XD	Plastic coin entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B2XS	Plastic coin entering into or through a natural orifice, sequela	10/1/2023
W44.B3XA	Plastic toy and toy part entering into or through a natural orifice, initial encounter	10/1/2023
W44.B3XD	Plastic toy and toy part entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B3XS	Plastic toy and toy part entering into or through a natural orifice, sequela	10/1/2023
W44.B4XA	Plastic jewelry entering into or through a natural orifice, initial encounter	10/1/2023
W44.B4XD	Plastic jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B4XS	Plastic jewelry entering into or through a natural orifice, sequela	10/1/2023
W44.B5XA	Plastic bottle entering into or through a natural orifice, initial encounter	10/1/2023
W44.B5XD	Plastic bottle entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B5XS	Plastic bottle entering into or through a natural orifice, sequela	10/1/2023
W44.B9XA	Other plastic object entering into or through a natural orifice, initial encounter	10/1/2023
W44.B9XD	Other plastic object entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.B9XS	Other plastic object entering into or through a natural orifice, sequela	10/1/2023
W44.C0XA	Glass unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.C0XD	Glass unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023

W44.C0XS	Glass unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.C1XA	Sharp glass entering into or through a natural orifice, initial encounter	10/1/2023
W44.C1XD	Sharp glass entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.C1XS	Sharp glass entering into or through a natural orifice, sequela	10/1/2023
W44.C2XA	Intact glass entering into or through a natural orifice, initial encounter	10/1/2023
W44.C2XD	Intact glass entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.C2XS	Intact glass entering into or through a natural orifice, sequela	10/1/2023
W44.D0XA	Magnetic metal object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.D0XD	Magnetic metal object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.D0XS	Magnetic metal object unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.D1XA	Magnetic metal bead entering into or through a natural orifice, initial encounter	10/1/2023
W44.D1XD	Magnetic metal bead entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.D1XS	Magnetic metal bead entering into or through a natural orifice, sequela	10/1/2023
W44.D2XA	Magnetic metal coin entering into or through a natural orifice, initial encounter	10/1/2023
W44.D2XD	Magnetic metal coin entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.D2XS	Magnetic metal coin entering into or through a natural orifice, sequela	10/1/2023
W44.D3XA	Magnetic metal toy entering into or through a natural orifice, initial encounter	10/1/2023
W44.D3XD	Magnetic metal toy entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.D3XS	Magnetic metal toy entering into or through a natural orifice, sequela	10/1/2023
W44.D4XA	Magnetic metal jewelry entering into or through a natural orifice, initial encounter	10/1/2023
W44.D4XD	Magnetic metal jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.D4XS	Magnetic metal jewelry entering into or through a natural orifice, sequela	10/1/2023
W44.D9XA	Other magnetic metal objects entering into or through a natural orifice, initial encounter	10/1/2023
W44.D9XD	Other magnetic metal objects entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.D9XS	Other magnetic metal objects entering into or through a natural orifice, sequela	10/1/2023
W44.E0XA	Non-magnetic metal object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.E0XD	Non-magnetic metal object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.E0XS	Non-magnetic metal object unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.E1XA	Non-magnetic metal bead entering into or through a natural orifice, initial encounter	10/1/2023
W44.E1XD	Non-magnetic metal bead entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.E1XS	Non-magnetic metal bead entering into or through a natural orifice, sequela	10/1/2023
W44.E2XA	Non-magnetic metal coin entering into or through a natural orifice, initial encounter	10/1/2023
W44.E2XD	Non-magnetic metal coin entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.E2XS	Non-magnetic metal coin entering into or through a natural orifice, sequela	10/1/2023
W44.E3XA	Non-magnetic metal toy entering into or through a natural orifice, initial encounter	10/1/2023

W44.E3XD	Non-magnetic metal toy entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.E3XS	Non-magnetic metal toy entering into or through a natural orifice, sequela	10/1/2023
W44.E4XA	Non-magnetic metal jewelry entering into or through a natural orifice, initial encounter	10/1/2023
W44.E4XD	Non-magnetic metal jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.E4XS	Non-magnetic metal jewelry entering into or through a natural orifice, sequela	10/1/2023
W44.E9XA	Other non-magnetic metal objects entering into or through a natural orifice, initial encounter	10/1/2023
W44.E9XD	Other non-magnetic metal objects entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.E9XS	Other non-magnetic metal objects entering into or through a natural orifice, sequela	10/1/2023
W44.F0XA	Objects of natural or organic material unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.F0XD	Objects of natural or organic material unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.F0XS	Objects of natural or organic material unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.F1XA	Bezoar entering into or through a natural orifice, initial encounter	10/1/2023
W44.F1XD	Bezoar entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.F1XS	Bezoar entering into or through a natural orifice, sequela	10/1/2023
W44.F2XA	Rubber band entering into or through a natural orifice, initial encounter	10/1/2023
W44.F2XD	Rubber band entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.F2XS	Rubber band entering into or through a natural orifice, sequela	10/1/2023
W44.F3XA	Food entering into or through a natural orifice, initial encounter	10/1/2023
W44.F3XD	Food entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.F3XS	Food entering into or through a natural orifice, sequela	10/1/2023
W44.F4XA	Insect entering into or through a natural orifice, initial encounter	10/1/2023
W44.F4XD	Insect entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.F4XS	Insect entering into or through a natural orifice, sequela	10/1/2023
W44.F9XA	Other object of natural or organic material, entering into or through a natural orifice, initial encounter	10/1/2023
W44.F9XD	Other object of natural or organic material, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.F9XS	Other object of natural or organic material, entering into or through a natural orifice, sequela	10/1/2023
W44.G0XA	Other non-organic objects unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.G0XD	Other non-organic objects unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.G0XS	Other non-organic objects unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.G1XA	Audio device entering into or through a natural orifice, initial encounter	10/1/2023
W44.G1XD	Audio device entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.G1XS	Audio device entering into or through a natural orifice, sequela	10/1/2023
W44.G2XA	Combination metal and plastic toy and toy part entering into or through natural orifice, initial encounter	10/1/2023
W44.G2XD	Combination metal and plastic toy and toy part entering into or through natural orifice, subsequent encounter	10/1/2023
W44.G2XS	Combination metal and plastic toy and toy part entering into or through natural orifice, sequela	10/1/2023

W44.G3XA	Combination metal and plastic jewelry entering into or through a natural orifice, initial encounter	10/1/2023
W44.G3XD	Combination metal and plastic jewelry entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.G3XS	Combination metal and plastic jewelry entering into or through a natural orifice, sequela	10/1/2023
W44.G9XA	Other non-organic objects entering into or through a natural orifice, initial encounter	10/1/2023
W44.G9XD	Other non-organic objects entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.G9XS	Other non-organic objects entering into or through a natural orifice, sequela	10/1/2023
W44.H0XA	Other sharp object unspecified, entering into or through a natural orifice, initial encounter	10/1/2023
W44.H0XD	Other sharp object unspecified, entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.H0XS	Other sharp object unspecified, entering into or through a natural orifice, sequela	10/1/2023
W44.H1XA	Needle entering into or through a natural orifice, initial encounter	10/1/2023
W44.H1XD	Needle entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.H1XS	Needle entering into or through a natural orifice, sequela	10/1/2023
W44.H2XA	Knife, sword or dagger entering into or through a natural orifice, initial encounter	10/1/2023
W44.H2XD	Knife, sword or dagger entering into or through a natural orifice, subsequent encounter	10/1/2023
W44.H2XS	Knife, sword or dagger entering into or through a natural orifice, sequela	10/1/2023
Z02.84	Encounter for child welfare exam	10/1/2023
Z05.81	Observation and evaluation of newborn for suspected condition related to home physiologic monitoring device ruled out	10/1/2023
Z05.89	Observation and evaluation of newborn for other specified suspected condition ruled out	10/1/2023
Z16.13	Resistance to carbapenem	10/1/2023
Z22.340	Carrier of carbapenem-resistant Acinetobacter baumannii	10/1/2023
Z22.341	Carrier of carbapenem-sensitive Acinetobacter baumannii	10/1/2023
Z22.349	Carrier of Acinetobacter baumannii, unspecified	10/1/2023
Z22.350	Carrier of carbapenem-resistant Enterobacterales	10/1/2023
Z22.358	Carrier of other Enterobacterales	10/1/2023
Z22.359	Carrier of Enterobacterales, unspecified	10/1/2023
Z29.81	Encounter for HIV pre-exposure prophylaxis	10/1/2023
Z29.89	Encounter for other specified prophylactic measures	10/1/2023
Z62.23	Child in custody of non-parental relative	10/1/2023
Z62.24	Child in custody of non-relative guardian	10/1/2023
Z62.823	Parent-step child conflict	10/1/2023
Z62.831	Non-parental relative-child conflict	10/1/2023
Z62.832	Non-relative guardian-child conflict	10/1/2023
Z62.833	Group home staff-child conflict	10/1/2023
Z62.892	Runaway [from current living environment]	10/1/2023

Z83.710	Family history of adenomatous and serrated polyps	10/1/2023
Z83.711	Family history of hyperplastic colon polyps	10/1/2023
Z83.718	Other family history of colon polyps	10/1/2023
Z83.719	Family history of colon polyps, unspecified	10/1/2023
Z91.85	Personal history of military service	10/1/2023
Z91.A41	Caregiver's other noncompliance with patient's medication regimen due to financial hardship	10/1/2023
Z91.A48	Caregiver's other noncompliance with patient's medication regimen for other reason	10/1/2023
Z91.A51	Caregiver's noncompliance with patient's renal dialysis due to financial hardship	10/1/2023
Z91.A58	Caregiver's noncompliance with patient's renal dialysis for other reason	10/1/2023
Z91.A91	Caregiver's noncompliance with patient's other medical treatment and regimen due to financial hardship	10/1/2023
Z91.A98	Caregiver's noncompliance with patient's other medical treatment and regimen for other reason	10/1/2023

[Back to top](#)

Table 4 - ICD-10-PCS Codes

Code	Description	Effective Date
02HW3RZ	Insertion of Short-term External Heart Assist System into Thoracic Aorta, Descending, Percutaneous Approach	10/1/2023
02PW3RZ	Removal of Short-term External Heart Assist System from Thoracic Aorta, Descending, Percutaneous Approach	10/1/2023
02WW3RZ	Revision of Short-term External Heart Assist System in Thoracic Aorta, Descending, Percutaneous Approach	10/1/2023
0CSS0ZZ	Reposition Larynx, Open Approach	10/1/2023
0CSS7ZZ	Reposition Larynx, Via Natural or Artificial Opening	10/1/2023
0CSS8ZZ	Reposition Larynx, Via Natural or Artificial Opening Endoscopic	10/1/2023
0DH17JZ	Insertion of Magnetic Lengthening Device into Upper Esophagus, Via Natural or Artificial Opening	10/1/2023
0DH27JZ	Insertion of Magnetic Lengthening Device into Middle Esophagus, Via Natural or Artificial Opening	10/1/2023
0DH37JZ	Insertion of Magnetic Lengthening Device into Lower Esophagus, Via Natural or Artificial Opening	10/1/2023
0WHC0GZ	Insertion of Defibrillator Lead into Mediastinum, Open Approach	10/1/2023
0WHC3GZ	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Approach	10/1/2023
0WHC4GZ	Insertion of Defibrillator Lead into Mediastinum, Percutaneous Endoscopic Approach	10/1/2023
0WPC0GZ	Removal of Defibrillator Lead from Mediastinum, Open Approach	10/1/2023
0WPC3GZ	Removal of Defibrillator Lead from Mediastinum, Percutaneous Approach	10/1/2023
0WPC4GZ	Removal of Defibrillator Lead from Mediastinum, Percutaneous Endoscopic Approach	10/1/2023
0WPCXGZ	Removal of Defibrillator Lead from Mediastinum, External Approach	10/1/2023
0WWC0GZ	Revision of Defibrillator Lead in Mediastinum, Open Approach	10/1/2023
0WWC3GZ	Revision of Defibrillator Lead in Mediastinum, Percutaneous Approach	10/1/2023
0WWC4GZ	Revision of Defibrillator Lead in Mediastinum, Percutaneous Endoscopic Approach	10/1/2023
0WWCXGZ	Revision of Defibrillator Lead in Mediastinum, External Approach	10/1/2023

5A09B5K	Assistance with Respiratory Ventilation, Less than 8 Consecutive Hours, Intubated Prone Positioning	10/1/2023
5A09C5K	Assistance with Respiratory Ventilation, 8-24 Consecutive Hours, Intubated Prone Positioning	10/1/2023
5A09D5K	Assistance with Respiratory Ventilation, Greater than 24 Consecutive Hours, Intubated Prone Positioning	10/1/2023
8E0U0EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Open Approach	10/1/2023
8E0U3EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Approach	10/1/2023
8E0U4EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Endoscopic Approach	10/1/2023
8E0U7EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening	10/1/2023
8E0U8EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening Endoscopic	10/1/2023
8E0W0EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Open Approach	10/1/2023
8E0W3EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Approach	10/1/2023
8E0W4EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Endoscopic Approach	10/1/2023
8E0W7EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening	10/1/2023
8E0W8EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening Endoscopic	10/1/2023
X05I329	Destruction of Renal Sympathetic Nerve(s) using Ultrasound Ablation, Percutaneous Approach, New Technology Group 9	10/1/2023
X2H03R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Inferior Vena Cava, Percutaneous Approach, New Technology Group 9	10/1/2023
X2H13R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Superior Vena Cava, Percutaneous Approach, New Technology Group 9	10/1/2023
X2H20R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Right Femoral Vein, Open Approach, New Technology Group 9	10/1/2023
X2H30R9	Insertion of Intraluminal Device, Bioprosthetic Valve into Left Femoral Vein, Open Approach, New Technology Group 9	10/1/2023
X2H63V9	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Atrium, Percutaneous Approach, New Technology Group 9	10/1/2023
X2HK3V9	Insertion of Dual-Chamber Intracardiac Pacemaker into Right Ventricle, Percutaneous Approach, New Technology Group 9	10/1/2023
X2HL0F9	Insertion of Conduit to Short-term External Heart Assist System into Right Axillary Artery, Open Approach, New Technology Group 9	10/1/2023
X2HM0F9	Insertion of Conduit to Short-term External Heart Assist System into Left Axillary Artery, Open Approach, New Technology Group 9	10/1/2023

X2HX0F9	Insertion of Conduit to Short-term External Heart Assist System into Thoracic Aorta, Ascending, Open Approach, New Technology Group 9	10/1/2023
X2KH3D9	Bypass Right Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
X2KH3E9	Bypass Right Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
X2KJ3D9	Bypass Left Femoral Artery using Conduit through Femoral Vein to Superficial Femoral Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
X2KJ3E9	Bypass Left Femoral Artery using Conduit through Femoral Vein to Popliteal Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
X2U4079	Supplement Coronary Artery/Arteries with Vein Graft Extraluminal Support Device(s), Open Approach, New Technology Group 9	10/1/2023
X2UQ0P9	Supplement Right Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	10/1/2023
X2UR0P9	Supplement Left Upper Extremity Vein with Synthetic Substitute, Extraluminal Support Device, Open Approach, New Technology Group 9	10/1/2023
XNHG0F9	Insertion of Tibial Extension with Motion Sensors into Right Tibia, Open Approach, New Technology Group 9	10/1/2023
XNHH0F9	Insertion of Tibial Extension with Motion Sensors into Left Tibia, Open Approach, New Technology Group 9	10/1/2023
XNR80D9	Replacement of Skull with Ultrasound Penetrable Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2023
XNRL099	Replacement of Right Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2023
XNRM099	Replacement of Left Tarsal with Talar Prosthesis Synthetic Substitute, Open Approach, New Technology Group 9	10/1/2023
XRJ0B9	Fusion of Right Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
XRK0B9	Fusion of Left Ankle Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
XRGL0B9	Fusion of Right Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
XRGM0B9	Fusion of Left Tarsal Joint using Open-truss Design Internal Fixation Device, Open Approach, New Technology Group 9	10/1/2023
XW013L9	Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	10/1/2023
XW013S9	Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9	10/1/2023
XW033K9	Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW033P9	Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023

XW033Q9	Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW033R9	Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW043K9	Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW043P9	Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW043Q9	Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW043R9	Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XW053T9	Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9	10/1/2023
XW0DXJ9	Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9	10/1/2023
XW0DXN9	Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9	10/1/2023
XWI33H9	Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XWI43H9	Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9	10/1/2023
XX20X89	Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9	10/1/2023
XX2F3W9	Monitoring of Musculoskeletal Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach, New Technology Group 9	10/1/2023
XXE2X19	Measurement of Cardiac Output, Computer-aided Assessment, New Technology Group 9	10/1/2023
XXE5XY9	Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9	10/1/2023

[Back to top](#)

Table 5 – Modifiers

Modifier	Description	Effective Date
N/A	N/A	N/A

[Back to top](#)

Table 6 – Outpatient Hospital

Code	Description	Effective Date
0408U	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])	10/1/2023
A9573	Injection, gadopiclesol, 1 ml	10/1/2023
A9603	Injection, pafolacianine, 0.1 mg	10/1/2023
A9697	Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose	10/1/2023
C9152	Injection, aripiprazole, (abilify asimtufii), 1 mg	10/1/2023
C9153	Injection, amisulpride, 1 mg	10/1/2023
C9154	Injection, buprenorphine extended-release (brixadi), 1 mg	10/1/2023

C9155	Injection, epcoritamab-bysp, 0.16 mg	10/1/2023
C9156	Flutofolastat f 18, diagnostic, 1 millicurie	10/1/2023
C9157	Injection, tofersen, 1 mg	10/1/2023
C9158	Injection, risperidone, (uzedy), 1 mg	10/1/2023
C9791	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	10/1/2023
H2040	Coordinated specialty care, team-based, for first episode psychosis, per month	10/1/2023
H2041	Coordinated specialty care, team-based, for first episode psychosis, per encounter	10/1/2023
J0349	Injection, rezafungin, 1 mg	10/1/2023
J0801	Injection, corticotropin (acthar gel), up to 40 units	10/1/2023
J0802	Injection, corticotropin (ani), up to 40 units	10/1/2023
J0874	Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg	10/1/2023
J0889	Daprodustat, oral, 1 mg, (for esrd on dialysis)	10/1/2023
J2359	Injection, olanzapine, 0.5 mg	10/1/2023
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	10/1/2023
J7214	Injection, factor viii/von willebrand factor complex, recombinant (altuviio), per factor viii i.u.	10/1/2023
J7519	Injection, mycophenolate mofetil, 10 mg	10/1/2023
J9064	Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg	10/1/2023
J9345	Injection, retifanlimab-dlwr, 1 mg	10/1/2023

[Back to top](#)

Table 7 – Codes that require a Pre-Pay or Post-Pay claim review.

[Back to top](#)

Code	Description	Effective Date	Special Billing Information
C9155	Injection, epcoritamab-bysp, 0.16 mg	10/1/2023	PA Required Min Age: 18 Max Units: 300
C9157	Injection, tofersen, 1 mg	10/1/2023	PA Required Min Age: 18 Max Units: 100
C9791	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	10/1/2023	PA Required Min Age: 12 Max Units: 1
J0349	Injection, rezafungin, 1 mg	10/1/2023	PA Required Min Age: 18 Max Units: 400

J278I	Injection, pegcetacoplan, intravitreal, 1 mg	10/1/2023	PA Required Min Age: 18 Max Units: 30
J9345	Injection, retifanlimab-dlwr, 1 mg	10/1/2023	PA Required Min Age: 18 Max Units: 500

[Back to top](#)

Table 8 – Non-covered codes

Code	Desc
0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations
0402U	Infectious agent (STI), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each Pathogen
0403U	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer
0404U	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression
0405U	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected
0406U	Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer
0407U	Nephrology (diabetic chronic kidney disease), multiplex electrochemiluminescent immunoassay of soluble tumor necrosis factor receptor 1, soluble tumor necrosis receptor 2, & kidney injury molecule 1 combined w/ clinical data
0409U	Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, & fusions
0410U	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected
0411U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
0412U	Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age
0413U	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations
0414U	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), & KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded tissue

0415U	Cardiovascular disease (acute coronary syndrome), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN & MCP-3 by immunoassay combined w/ age, sex, family history, & personal hx of diabetes, blood, algorithm reported as a 5-year score
0416U	Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial & fungal organisms, including identification of 20 associated atb-resistance genes, if performed
0417U	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes
0418U	Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score
0419U	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype
A2022	Innovaburn or innovamatrix xl, per square centimeter
A2023	Innovamatrix pd, 1 mg
A2024	Resolve matrix, per square centimeter
A2025	Miro3d, per cubic centimeter
A9156	Oral mucoadhesive, any type (liquid, gel, paste, etc.), per 1 ml
A9268	Programmer for transient, orally ingested capsule
A9269	Programable, transient, orally ingested capsule, for use with external programmer, per month
A9292	Prescription digital visual therapy, software-only, fda cleared, per course of treatment
C9788	Opto-acoustic imaging, breast (including axilla when performed), unilateral, with image documentation, analysis and report, obtained with ultrasound examination
C9789	Instillation of anti-neoplastic pharmacologic/biologic agent into renal pelvis, any method, including all imaging guidance, including volumetric measurement if performed
C9790	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance
C9792	Blinded or nonblinded procedure for symptomatic new york heart association class ii, iii, iva heart failure; transcath implantation of lt atrial to coronary sinus shunt using jugular vein access, including all imaging
E0490	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote
E0491	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply
H2040	Coordinated specialty care, team-based, for first episode psychosis, per month
H2041	Coordinated specialty care, team-based, for first episode psychosis, per encounter
J7353	Anacaulase-bcdb, 8.8% gel, 1 gram
J9051	Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg
K1036	Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month
L5991	Addition to lower extremity prostheses, osseointegrated external prosthetic connector

Q4285	Nudyn dl or nudyn dl mesh, per square centimeter
Q4286	Nudyn sl or nudyn slw, per square centimeter
V2526	Contact lens, hydrophilic, with blue-violet filter, per lens

[Back to top](#)

Table 9 – Deleted Codes

Code	Desc	Effective Date	Replacement Code (if applicable)
0066U	Placental alpha-micro globulin-I (PAMG-I), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen	9/30/2023	
0357U	Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents	9/30/2023	
0386U	Gastroenterology (Barrett’s esophagus), PI6, RUNX3, HPPI, and FBNI methylation analysis, prognostic and predictive algorithm reported as a risk score for progression to high-grade dysplasia or esophageal cancer	9/30/2023	
0397U	Oncology (non-small cell lung cancer), cell-free DNA from plasma, targeted sequence analysis of at least 109 genes, including sequence variants, substitutions, insertions, deletions, select rearrangements, and copy number variations	9/30/2023	
C915I	Injection, pegcetacoplan, 1 mg	9/30/2023	J278I
J0800	Injection, corticotropin, up to 40 units	9/30/2023	

[Back to top](#)